低分子量肝素(low molecular weight heparin,LMWH) 名词解释 2024-08-10 21:11:58 0 14 参考答案:低分子量肝素是由普通肝素直接分离... 查看答案 课程:药理学 学科:药学 感兴趣题目 溶栓药(thrombolytics) 胆碱酯酶能与ACh结合的活性中心包括 新斯的明可治疗 氯解磷定的特点是 治疗重症肌无力可选用的药物是...
平台编号:140647 CAS.NO:批号140647-201602 浓度/规格:约10mg/支;供效价测定用;-20℃,避光 是否有货:有货 购买数量: -1+ 注意事项:本网站销售的所有产品仅用于工业应用或者科学研究等,不可用于人类或动物的临床诊断或治疗,非药用,非食用。 详细信息 ...
肝素(unfractionated heparin)与低分子肝素(lowmolecularweightheparin)都是葡萄糖胺和糖醛酸双糖单位链组成的葡糖胺聚糖。目…emuch.net|基于1 个网页 2. 低分子量肝素 (3)低分子量肝素(lowmolecularweightheparin):在小儿应用渐广,可用于小儿缺血性脑梗死的早期(周水珍等,2001)。DeVeber(19…kepu.yiwang.cn|基于...
Low molecular weight heparins (LMWHs) are mixtures of heparin molecules in the range of 3000 to 10,000 daltons. As LMWHs of various manufacturers are all produced differently, they are not comparable to each other and are therefore considered to be individual products with different pharmacologic...
低分子量肝素钙注射液药品报告提供了低分子量肝素钙注射液的各种信息,包括低分子量肝素钙注射液的药品简介,新药研发进度,仿制药申报进度,中国药品注册情况,一致性评价进度,药品临床试验进度,药品上市等信息.更多药物报告的查询就在戊戌数据药物报告数据库.
国家药品标准物质使用说明书 低分子量肝素 Low molecular weight heparin 【类别】 标准品 【批号】 140647-201602 【结构式】 / 【分子式】 / 【分子量】 / 【CAS 号】 9041-08-1 【用途】 供低分子量肝素抗 Xa 因子和抗 IIa 因子效价测定用.本品 抗 Xa 因子效价为 1497 IU/安瓿,抗 IIa 因子效价为...
Low-molecular-weight heparins are effective for treating venous thrombosis, but their cost-effectiveness has not been rigorously assessed. MK Gould,AD Dembitzer,RL Doyle,... - 《Annals of Internal Medicine》 被引量: 4273发表: 1999年 A comparison of low-molecular-weight heparin administered primar...
Low Molecular Weight Heparin (LMWH) was obtained by controlled nitrous acid degradation of standard heparin(SH). 目的:观察低分子量肝素钠(Low molecular weight heparin,LMWH)在大鼠动静脉旁路血栓模型上的抗血栓形成作用和对家兔凝血、纤溶系统的影响。 更多例句>> 补充...
1. Clinical study on the curative effect of Shuxuetong injection and low molecular weight heparin on frequent transient ischemic attack; 疏血通联合低分子肝素钙治疗频发短暂性脑缺血发作的临床观察2. Objective To study the clinical effects of Xueshuantong with low molecular weight heparin for unstable ...
A low-molecular-weight heparin (LMWH) has been compared to conventional heparin in haemodialysis in a 12-month study. In a group of 22 patients who had been on chronic haemodialysis for longer than 12 months, the conventional, unfractionated heparin was replaced by a low-molecular-weight analogu...